Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

ASCO News In Brief: Allergan Ligand Retinoid Therapeutics ALRT1057

  • News

Executive Summary

Allergan Ligand Retinoid Therapeutics ALRT1057: Interim findings of Phase I/II Memorial Sloan-Kettering Cancer Center trial of 9-cis retinoic acid capsules used in the treatment of 15 acute promyelocytic leukemia patients results in 40% complete remission rate for durations of two to 18 months. Unlike ALRT1057, all-trans retinoic acid maintenance therapy for APL often results in retinoid resistance within a few months of treatment, the company said. Irvine, Calif.-based ALRT will begin Phase II/III with ALRT1057 trials this year...

Table

View full table

Tags:
Latest Headlines

EU & South Korea Sign Deal On Exchange Of Confidential Information

Recent And Upcoming FDA Advisory Committee Meetings

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

See All
UsernamePublicRestriction

Register

PS028194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By